Equities Analysts Offer Predictions for AUTL Q3 Earnings

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) – Analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for shares of Autolus Therapeutics in a research note issued to investors on Monday, November 2nd. HC Wainwright analyst D. Tsao anticipates that the company will post earnings of ($0.20) per share for the quarter. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.74) per share. HC Wainwright also issued estimates for Autolus Therapeutics’ Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.81) EPS, FY2027 earnings at ($0.74) EPS, FY2028 earnings at ($0.86) EPS, FY2029 earnings at ($0.73) EPS and FY2030 earnings at ($0.26) EPS.

AUTL has been the topic of a number of other reports. Wall Street Zen upgraded Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, August 16th. Weiss Ratings cut Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Autolus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Autolus Therapeutics Stock Performance

AUTL opened at $1.42 on Wednesday. The business has a 50 day moving average price of $1.87 and a two-hundred day moving average price of $1.67. The company has a market capitalization of $376.62 million, a price-to-earnings ratio of -1.33 and a beta of 2.32. Autolus Therapeutics has a 1-year low of $1.18 and a 1-year high of $2.58. The company has a debt-to-equity ratio of 1.04, a current ratio of 4.89 and a quick ratio of 4.40.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.06. The business had revenue of $45.69 million during the quarter, compared to analyst estimates of $38.56 million. Autolus Therapeutics had a negative return on equity of 178.66% and a negative net margin of 238.66%.

Institutional Trading of Autolus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Syncona Portfolio Ltd acquired a new stake in Autolus Therapeutics during the second quarter valued at $26,625,152. Cetera Investment Advisers increased its position in Autolus Therapeutics by 2.7% in the 1st quarter. Cetera Investment Advisers now owns 1,129,074 shares of the company’s stock worth $1,558,000 after purchasing an additional 29,324 shares during the last quarter. Alphabet Inc. acquired a new position in Autolus Therapeutics in the 2nd quarter worth about $1,117,000. Privium Fund Management B.V. increased its position in Autolus Therapeutics by 29.2% in the 3rd quarter. Privium Fund Management B.V. now owns 469,490 shares of the company’s stock worth $911,000 after purchasing an additional 106,060 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. raised its stake in shares of Autolus Therapeutics by 2.5% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 451,403 shares of the company’s stock worth $722,000 after purchasing an additional 11,197 shares in the last quarter. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing programmed T-cell therapies for cancer. The company’s approach is designed to engineer T cells to recognize and eliminate malignant cells while incorporating features intended to improve activity, persistence and safety.

Its lead product, obecabtagene autoleucel, is an autologous CAR T-cell therapy marketed in the United States under the brand name Aucatzyl. It is used to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.